Literature DB >> 27264648

Rutin-encapsulated chitosan nanoparticles targeted to the brain in the treatment of Cerebral Ischemia.

Niyaz Ahmad1, Rizwan Ahmad2, Atta Abbas Naqvi3, Md Aftab Alam4, Mohammad Ashafaq5, Mohd Samim6, Zeenat Iqbal7, Farhan Jalees Ahmad7.   

Abstract

OBJECTIVE: Rutin, a potent antioxidant, has been reported to reduce the risk of ischemic disease. Our study aims to prepare rutin-encapsulated-chitosan nanoparticles (RUT-CS-NPs) via ionic gelation method and determine its results, based on different parameters i.e. surface morphology characterization, in-vitro or ex-vivo release, dynamic light scattering and differential scanning calorimetry (DSC), for treating cerebral ischemia.
METHODS: UPLC-ESI-Q-TOF-MS/MS was used to evaluate the optimized RT-CS-NPs1 for brain-drug uptake as well as to follow-up the pharmacokinetics, bio-distrbution, brain-targeting efficiency and potential after intranasal administration (i.n.). KEY
FINDINGS: A particle size of <100nm for the formulation, significantly affected by drug:CS ratio, and entrapment efficiency and loading capacity of 84.98%±4.18% and 39.48%±3.16%, respectively were observed for RUT. Pharmacokinetics, bio-distribution, brain-targeting efficiency (1443.48±39.39%) and brain drug-targeting potential (93.00±5.69%) showed enhanced bioavailability for RUT in brain as compared to intravenous administration. In addition; improved neurobehavioral activity, histopathology and reduced infarction volume effects were observed in middle cerebral artery occlusion (MCAO) induced cerebral ischemic rats model after i.n. administration of RUT-CS-NPs.
CONCLUSION: A significant role of mucoadhesive-RT-CS-NPs1 as observed after high targeting potential and efficiency of the formulation prove; RUT-CS-NPs are more effectively accessed and target easily the brain.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain pharmacokinetics and pharmacodynamics; Cerebral ischemia; Chitosan nanoparticles; Rutin; UPLC–MS/MS method validation

Mesh:

Substances:

Year:  2016        PMID: 27264648     DOI: 10.1016/j.ijbiomac.2016.06.001

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  19 in total

Review 1.  Nanoparticle-Based Therapeutics for Brain Injury.

Authors:  Vimala N Bharadwaj; Duong T Nguyen; Vikram D Kodibagkar; Sarah E Stabenfeldt
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 2.  Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS.

Authors:  Anupam Sarma; Malay K Das
Journal:  Mol Biomed       Date:  2020-12-10

Review 3.  Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version.

Authors:  Jiaxi Xie; Cailing Zhong; Tingting Wang; Dan He; Luyang Lu; Jie Yang; Ziyi Yuan; Jingqing Zhang
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

4.  Pterostilbene induces Nrf2/HO-1 and potentially regulates NF-κB and JNK-Akt/mTOR signaling in ischemic brain injury in neonatal rats.

Authors:  Qinghuang Zeng; Wenchang Lian; Guizhi Wang; Manping Qiu; Lingmu Lin; Renhe Zeng
Journal:  3 Biotech       Date:  2020-04-04       Impact factor: 2.406

Review 5.  Oral and Intra-nasal Administration of Nanoparticles in the Cerebral Ischemia Treatment in Animal Experiments: Considering its Advantages and Disadvantages.

Authors:  Firoozeh Alavian; Nasrin Shams
Journal:  Curr Clin Pharmacol       Date:  2020

6.  Repeated Iron-Soot Exposure and Nose-to-brain Transport of Inhaled Ultrafine Particles.

Authors:  Laurie E Hopkins; Emilia A Laing; Janice L Peake; Dale Uyeminami; Savannah M Mack; Xueting Li; Suzette Smiley-Jewell; Kent E Pinkerton
Journal:  Toxicol Pathol       Date:  2017-09-15       Impact factor: 1.902

7.  Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease.

Authors:  Xiao-Ying Sun; Ling-Jie Li; Quan-Xiu Dong; Jie Zhu; Ya-Ru Huang; Sheng-Jie Hou; Xiao-Lin Yu; Rui-Tian Liu
Journal:  J Neuroinflammation       Date:  2021-06-11       Impact factor: 8.322

8.  The Protective Effects of Juglanin in Cerebral Ischemia Reduce Blood-Brain Barrier Permeability via Inhibition of VEGF/VEGFR2 Signaling.

Authors:  Jia Liu; Lei Chen; Xin Zhang; Lixiao Pan; Lili Jiang
Journal:  Drug Des Devel Ther       Date:  2020-08-05       Impact factor: 4.162

9.  The Potential of Biomaterial-Based Approaches as Therapies for Ischemic Stroke: A Systematic Review and Meta-Analysis of Pre-clinical Studies.

Authors:  Faye Bolan; Irene Louca; Calvin Heal; Catriona J Cunningham
Journal:  Front Neurol       Date:  2019-08-27       Impact factor: 4.086

10.  Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia.

Authors:  Niyaz Ahmad; Rizwan Ahmad; Farhan Jalees Ahmad; Wasim Ahmad; Md Aftab Alam; Mohd Amir; Abuzer Ali
Journal:  Saudi J Biol Sci       Date:  2019-11-22       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.